Rnai-mediated inhibition of hif1a for treatment of ocular...

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/11 (2006.01) A61K 31/7105 (2006.01) A61P 27/02 (2006.01)

Patent

CA 2632595

RNA interference is provided for inhibition of HIFlA mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

L'ARN interférent est mis en oeuvre pour inhiber l'expression de l'ARNm de HIF1A, en vue de traiter des patients atteints d'angiogenèse oculaire, notamment pour traiter l'oedème rétinien, la rétinopathie diabétique, des séquelles associées à l'ischémie rétinienne, à la néovascularisation du segment postérieur (PSNV), au glaucome néovasculaire, et pour traiter des patients susceptibles de développer ces affections.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Rnai-mediated inhibition of hif1a for treatment of ocular... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Rnai-mediated inhibition of hif1a for treatment of ocular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rnai-mediated inhibition of hif1a for treatment of ocular... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1612750

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.